

Freedom Laser, Inc.

Quit Smoking Laser Device

VENTURE PROFILE

This Profile is not a solicitation to sell securities.

Freedom Laser, Inc.
FREEDOM[®]
Laser, Inc.

\$1,400,000
2021
10% Convertible
Debentures

Financing and Escrow arranged through
Sterling Capital One

Overview

Introducing the World's First Patented, Home Use Quit Smoking Laser Device. This revolutionary rechargeable device is a drug-free, highly effective, painless smoking cessation method. Its 21st Century technology is unparalleled in design, quality, and comfortability. This market disruptive product will potentially rival that of Edison, Disney, Uber and Tesla. The advanced low-level laser system intended to stimulate endorphins in the brain, will bring the promise of addiction relief to millions of smokers. Additional indications of use for the device include vaping and opioid addiction. In addition, there is an array of future applications for temporary pain relief of muscles and joints, including low-level laser therapy's healing affects to treat migraines, headaches, arthritis, TMJ, depression and anxiety.

Strategic Plan

Freedom Laser completed an Animal Study and a 25-day, 28-human subject, Institutional Review Board Approved Pilot Study which showed a 50% reduction in smoking. Freedom Laser is validating the technology in an FDA Trial in early 2021. Our biomedical experts are extremely confident based on our September 2020 quit smoking laser pilot study results, that an FDA clearance will be awarded from the upcoming 3-month clinical trial with 160 subjects. Upon FDA clearance, the company will be authorized to sell the tech in the US as a Prescription Medical Device.

Marketing & Sales Strategy

There are approximately 34 million smokers in the United States alone. Nearly 70% of them would like to quit and less than 5% achieve lasting success. Initially, the product will be marketed and sold to medical providers (Kaiser), medical device companies (Cardinal Health) and medical supply companies. The UCR price for the device will be \$495.

Doctors (AMA) and Dentists (ADA) will prescribe it for their patients that smoke. For patients utilizing their health insurance, it will be virtually free. It will be distributed through major online pharmaceutical retailers (CVS, Walgreens, and Amazon). Smokers spend an average of

\$4,000 annually on smoking; and, as the future medical costs from smoking are enormous, the cost / benefit, value proposition is truly compelling.

Management

Craig Nabat, the President of Freedom Laser, Inc. an ex-smoker who is the visionary behind the Device. Mr. Nabat has been researching nicotine addiction and treated more than 10,000 smokers and vapers in a clinical setting for the last 17 years. Nabat is driven to assist smokers in quitting.

Competition

There is no direct competitor for the Freedom home-use laser device. In a \$6 billion worldwide market for stop smoking products, the most popular methods assisting smokers to quit utilize a nicotine delivery system. The assortment of methods used to quit smoking include gums, e-cigarettes, pills, lozenges, inhalers, and sprays. These products are predominantly produced by Altria Group (MO), Pfizer (PFE) and GlaxoSmithKline (GSK).

The Freedom Quit Smoking Laser Device is worn twice daily for 15-minute sessions over 3 months



The Opportunity

For Investors that wish to be part of launching the first medical grade laser therapy device aimed to reduce smoking worldwide, Freedom presents a ground floor investment into a multi-billion-dollar market with unlimited growth potential combating nicotine addiction.

Projected Financial Highlights

The financial highlights below are excerpts of complete information contained in the company's pro forma financial statements and Offering Memorandum.

	Year 1	Year 2	Year 3
REVENUE	\$9,171,510	\$23,661,000	\$44,065,000
NET INCOME	\$1,982,054	\$8,806,779	\$16,433,215
EPS \$	0.40	1.59	2.97
STOCK PRICE AT 100 MULTIPLE	40	159	297

Contact Information

Mr. Adam De Michele, MBA, CPA,
Senior Partner Sterling Capital One
2901 West Coast Highway, Suite 200
Newport Beach, CA 92663
Sterlingcapitalllc@gmail.com
949.270.2929; cell 949.701.2555

Learn more at:
freedomquit.com